Hemophilia Treatment Market

Hemophilia Treatment Market by Product (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics), by Type (Hemophilia A, Hemophilia B, Hemophilia C) - Global Forecast to 2020

Report Code: UC 1580 Dec, 2018, by marketsandmarkets.com

The hemophilia treatment market is witnessing continuous growth. Increasing number of hemophilic patients worldwide is driving the demand for recombinant and plasma derived factor VIII and factor IX, which are used to treat hemophilia. In addition, increased diagnosis rate and rise in the use of prophylactic treatment for hemophilia are expected to propel the growth of this market. However, the high cost of recombinant products, serious adverse effects associated with plasma derived products, and stringent government regulations are hampering the growth of the global hemophilia market to a certain extent.

In this report, the hemophilia treatment market is segmented by product, type, and region. Based on type of product, the hemophilia treatment market is mainly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytics. Plasma derived coagulation factor concentrates is further subsegmented into factor VIII, factor IX, factor XIII, active promthrombin complex concentrates, and von Willebrand factor. Recombinant coagulation factor concentrates is further sugsegmented into factor VIII, factor IX, and von Willebrand factor. By type, hemophilia treatment market is segmented into hemophilia A, hemophilia B, and hemophilia C.

North America is the largest regional segment of the global hemophilia market. However, the APAC and Latin American regions are expected to witness significant growth in the near future, primarily rising number of hemophilic patients, and increasing awareness about technologically advanced products in these regions. Moreover, owing to better diagnostic technique, increasing prophylactic treatments, and growing medical research in the APAC and LATAM, the demand for recombinant and plasma derived products are further increasing in these regions.

The global hemophilia market is mainly dominated by six players that accounted for around 90% of the global hemophilia market in 2013. However, new local players in the market are intensifying competition and thereby threatening the market share of existing players. In order to maintain their shares, leading players are continuously adopting various strategies. This increased competitiveness is expected to drive innovation in the market and thereby help the industry to solve existing challenges and meet the needs of the market.

The major players in the global hemophilia market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer, Inc. (U.S.), Bayer AG (Germany), Biogen Idec, Inc. (U.S.), and Hospira, Inc. (U.S.) .

Scope of the Report

Plasma derived coagulation factor concentrates and recombinant coagulation factor concentrates are the primary drug of choice for the treatment of hemophilia. Increasing number of hemophilic patients across the globe is increasing the demand of hemophilia treatment products such plasma derived coagulation factor concentrates, recombinant coagulation factor, desmopressin, and antifibrinolytics.

Global Hemophilia Treatment Market

This research report categorizes the hemophilia treatment market into the following segments:

Hemophilia Treatment Market, by product

  • Plasama derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Factor XIII
    • Activated prothrombin complex concentrate
    • Von willebrand factor
  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Von willebrand factor
  • Desmopressin
  • Antifibrinolytic agents

Hemophilia Treatment Market, by type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Global Hemophilia Treatment Market, By Region

  • North America
      • U.S.
      • Canada
  • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
  • Asia-Pacific
      • Japan
      • China
      • India
      • Rest of Asia-Pacific
  • Rest of the World (RoW)
      • Latin America
      • Middle East and Africa

Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
UC 1580
Published ON
Dec, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Hemophilia Treatment Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved